Monogram Orthopaedics (MGRM) Company Overview

Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Request Management Anticipates a Comprehensive AIR Response in Q1 2025 AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application"). The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.

Monogram Technologies Inc. (NASDAQ:MGRM ) Q3 2024 Earnings Call Transcript November 19, 2024 4:30 PM ET Company Participants Ben Sexson - CEO Noel Knape - CFO Larry Holub - IR Conference Call Participants Tom Kerr - Zacks Investment Research Operator Greetings and welcome to the Monogram Technologies Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

AUSTIN, TX / ACCESSWIRE / October 16, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will attend the LD Micro Main Event XVII Conference being held at the Luxe Sunset Blvd Hotel in Los Angeles, CA October 29 - 30, 2024. Monogram Chief Financial Officer Noel Knape will conduct in-person one-on-one meetings during the conference to discuss the Company's novel mBôs precision robotic surgical system.

Company Has 180 Days From Receipt to Produce Additional Information AUSTIN, TX / ACCESSWIRE / October 3, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced a correction to its press release issued on Wednesday, October 2, 2024, entitled "Monogram Technologies Receives FDA Response for mBôs TKA System" (the "Prior Press Release"). In yesterday's prior press release, dated October 2, 2024, it was stated in the subtitle that: "Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days.

Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has received an Additional Information Request ("AIR") from the U.S. Food and Drug Administration ("FDA") on September 30, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application"). The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.

AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024.

AUSTIN, TX / ACCESSWIRE / September 11, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced an upsize of its previously announced continuous offering of units from $10 million to $12.5 million of units. Each unit consists of (a) one share of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") and (b) one common stock purchase warrant to purchase one share of its common stock, $0.001 par value per share (the "Common Stock").

Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System Secured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby Limited Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / August 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the second quarter ended June 30, 2024.

Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA System Strategic Partner Shalby is Recognized as one of the Leading Institutions for Orthopedic Surgeries Worldwide, Performing Over 14,000 Annual Knee Replacement Surgeries Globally AUSTIN, TX / ACCESSWIRE / August 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced its strategic collaboration with Shalby Limited (NSE:SHALBY) ("Shalby"), a global muti-specialty hospital chain and one of India's leading orthopedic hospital groups, to conduct a multicenter clinical trial to demonstrate the safety and effectiveness of the mBȏs TKA System.Shalby is the largest (ranked #1 in arthroplasty by volume) orthopedic hospital chain in the world employing over 4,000 people at 14 hospitals in 13 cities and more than 3 million patients treated. Shalby represents approximately 15% of the organized arthroplasty market in India, which has an approximate market size of 200,000 TKAs per year (with a compound annual growth rate of approximately 20% and a population of 1.4 billion people).